Trial: Assessing Treatment Efficacy Among Migraine Patients

December 2nd, 2019 Posted by Uncategorized 0 thoughts on “Trial: Assessing Treatment Efficacy Among Migraine Patients”

1nHealth is proud to announce that recruitment is underway for a clinical trial tasked with testing the safety and efficacy of a treatment option designed to benefit migraine sufferers.


A migraine occurs when calcitonin gene-related peptide (CGRP) molecules cause blood vessels to dilate, thereby releasing neurotransmitters that create pain.

Migraines are often associated with forms of depression, and although non-life-threatening, symptoms can be unbearable. Such symptoms include: severe head pain, nausea/vomiting, sensitivity to light, aura (flashes of light, blind spots, etc.), fatigue, and loss of vision/blurred vision.

While there is no known cure for migraines, there is a plethora of treatment options. Unfortunately, no specific treatment option works universally among migraine sufferers, and well over half of these individuals are unsatisfied with their current treatment plan. Therefore, there is a significant need for the development of additional treatments.

Existing Treatment Options

Existing therapies can primarily be sorted into two categories: preventative treatments and acute “relief” treatments. Preventative medications are intended to reduce the occurrence and intensity of migraines, while acute medications are to be taken at the outset of migraine symptoms.

The following table details existing treatments on the market:

Preventative Treatments Acute Treatments
Botox injections – Small injections around the head and neck areas can reduce the frequency of migraines. Triptans – These serotonin receptor agonists are taken orally, via nasal spray, etc., and are effective in relieving migraine symptoms.
Antidepressants – Research suggests that antidepressants containing amitriptyline have the potential to prevent migraines. Pain relievers – Analgesics and NSAIDs (ex. Tylenol) are an effective option for alleviating migraines and typically available over-the-counter.
Anti-seizure drugs – Anticonvulsants housing topiramate or valproate are known to reduce migraine frequency. Dihydroergotamines – To be taken as a nasal spray or injection, dihydroergotamines are most effective if taken once symptoms begin.
CGRP inhibitors – CGRP molecules cause migraine pain; CGRP inhibitors dull the effects of this discomfort. Anti-nausea drugs – Most often combined with pain medications, anti-nausea drugs (chlopromazine) reduce nausea and vomiting.
Beta blockers – Blood-pressure-lowering medications containing propranolol or metoprolol can prevent migraines. Opioids – Often seen as a last resort, opioid medications are dopamine receptor antagonists to be used when other treatments prove to be ineffective.

Study Specifics

The 1nHealth team is recruiting male/female participants, ages 18 to 65, living within a 25-mile radius of Los Alamitos, CA. Potential participants must have at least a one-year history of migraines (with or without aura), according to the International Classification of Headache Disorder.

The study requires one or more visits to a physical site location for physical assessment, and participants will be asked to consume the study product regularly. Compensation is available for those who complete the clinical trial while demonstrating protocol compliance.

Applying to the study is straightforward, quick, and painless. All you’ll need is access to the internet in order to register and complete a brief survey. If you qualify, a member of our study team will contact you to schedule a visit to your nearest clinic location. Interested in learning more? Click the button below.

Leave a Reply

Your email address will not be published. Required fields are marked *